SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery

SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development

SOHM, Inc., Moving and Expanding Commercialization Capabilities with its New Vista, CA Facility

SOHM Achieves Breakthrough with ABBIE Gene Editing Platform, Advancing Strategic Partnership and Licensing Opportunities

SOHM, Inc. Launches New User-Friendly Website to Enhance Customer, Investor Experience and Engagement

SOHM, Inc. Appoints Ravi Kapoor as an Independent Director

SOHM, Inc. Sets Strategic Goals to Enter Biotechnology-Driven Cosmeceuticals Market

SOHM Inc. Welcomes Dr. Larissa Karnaoukhova as New Vice President of Operations

SOHM Inc. Welcomes Dr. Lucia Piccotti to Offer Expert Guidance on Cosmeceutical and Personal Health Product Research and Development

SOHM, Inc., Unveils Genetically Engineered Ovarian Cancer Cell Line Using ABBIE(TM) Platform to Accelerate GYS1 Drug Discovery

Dr. Leonardo Mirandola Joins SOHM, Inc. as an Advisory Board to Advance CAR-T Cell Projects Toward Clinical Trials and Commercialization

SOHM Inc. Awarded European Patent for Innovative ABBIE Genome Editing Technology

SOHM, Inc. Announces Patent Allowance/Approval in South Korea

SOHM, Inc. Shares an Exciting Expansion and Upcoming Presentation on ABBIE

SOHM, Inc. Launches New AI Team to Advance ABBIE System and Genome Editing Innovations

SOHM, Inc. Shares Groundbreaking Findings in ABBIE Technology